Brian Piper - 17 Feb 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: EVP, Chief Financial Officer
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Brian Piper
Issuer symbol: SANA
Transactions as of: 17 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 18 Feb 2026, 16:35:39 UTC
Previous filing: 27 Aug 2021
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Piper Brian	EVP, Chief Financial Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE	/s/ Aaron M. Grossman, Attorney-in-Fact for Brian Piper	18 Feb 2026	0001665924

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SANA	Restricted Stock Units	Award	$0	+200,000		$0.000000	200,000	17 Feb 2026	Common Stock	200,000		Direct	F1, F2
transaction	SANA	Stock Option (Right to Buy)	Award	$0	+900,000		$0.000000	900,000	17 Feb 2026	Common Stock	900,000	$3.85	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2	The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3	The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.